Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRXNASDAQ:APLTNASDAQ:GANXNASDAQ:IMMX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsAPLTApplied Therapeutics$0.49+10.2%$0.43$0.30▼$10.62$68.69M23.24 million shs1.87 million shsGANXGain Therapeutics$1.86-3.6%$1.94$0.89▼$3.19$54.73M0.17306,327 shs421,678 shsIMMXImmix Biopharma$1.98$1.76$1.26▼$2.71$55.11M0.27122,489 shs44,014 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%APLTApplied Therapeutics-4.86%+8.16%+18.43%-18.70%-90.07%GANXGain Therapeutics+0.52%+1.90%+14.68%-23.11%-20.25%IMMXImmix Biopharma-5.26%+1.54%+26.52%-0.50%-8.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx Pharmaceuticals0.0973 of 5 stars0.00.00.03.90.00.00.0APLTApplied Therapeutics3.9045 of 5 stars3.32.00.04.71.62.50.6GANXGain Therapeutics2.2616 of 5 stars3.63.00.00.02.10.80.6IMMXImmix Biopharma2.76 of 5 stars3.53.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/AAPLTApplied Therapeutics 2.50Moderate Buy$6.101,157.21% UpsideGANXGain Therapeutics 3.17Buy$8.20340.86% UpsideIMMXImmix Biopharma 3.00Buy$7.00253.54% UpsideCurrent Analyst Ratings BreakdownLatest ACRX, IMMX, APLT, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.503/28/2025GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/17/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025GANXGain TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform ➝ Sector Outperform$12.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00APLTApplied Therapeutics$455K150.97N/AN/A($0.20) per share-2.43GANXGain Therapeutics$50K1,094.68N/AN/A$0.97 per share1.92IMMXImmix BiopharmaN/AN/AN/AN/A$0.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/AAPLTApplied Therapeutics-$119.76M-$0.95N/AN/AN/AN/A-260.75%-76.04%5/15/2025 (Estimated)GANXGain Therapeutics-$22.27M-$0.92N/AN/AN/AN/A-203.91%-128.05%5/14/2025 (Estimated)IMMXImmix Biopharma-$15.43M-$0.77N/AN/AN/AN/A-102.68%-80.89%5/15/2025 (Estimated)Latest ACRX, IMMX, APLT, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q4 2024APLTApplied Therapeutics-$0.16$0.52+$0.68-$0.15$0.10 million$0.00 million5/15/2025Q1 2025IMMXImmix Biopharma-$0.23-$0.15+$0.08N/AN/AN/A5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04APLTApplied TherapeuticsN/A1.061.06GANXGain Therapeutics0.042.992.99IMMXImmix BiopharmaN/A3.473.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%APLTApplied Therapeutics98.31%GANXGain Therapeutics11.97%IMMXImmix Biopharma11.26%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%APLTApplied Therapeutics8.60%GANXGain Therapeutics11.70%IMMXImmix Biopharma48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionableGANXGain Therapeutics2029.43 million23.42 millionOptionableIMMXImmix Biopharma927.83 million14.06 millionOptionableACRX, IMMX, APLT, and GANX HeadlinesRecent News About These CompaniesImmix Biopharma (IMMX) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 44.8% in AprilMay 1, 2025 | marketbeat.comImmix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025April 23, 2025 | globenewswire.comImmix Biopharma stock holds $7 target, Buy rating at H.C. WainwrightFebruary 11, 2025 | msn.comImmix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL AmyloidosisFebruary 11, 2025 | markets.businessinsider.comBuy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201February 10, 2025 | tipranks.comImmix Biopharma, Inc. Receives FDA RMAT Designation for CAR-T Therapy NXC-201 in Relapsed/Refractory AL AmyloidosisFebruary 10, 2025 | quiverquant.comImmix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL AmyloidosisFebruary 10, 2025 | globenewswire.comSeveral Insiders Invested In Immix Biopharma Flagging Positive NewsFebruary 5, 2025 | finance.yahoo.comImmix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201January 8, 2025 | markets.businessinsider.comImmix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-TJanuary 7, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)January 6, 2025 | markets.businessinsider.comImmix Biopharma Reports Positive Early Results From NEXICART-2 Trial Of NXC-201 In AL AmyloidosisDecember 19, 2024 | markets.businessinsider.comImmix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) AmyloidosisDecember 19, 2024 | globenewswire.comImmix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 19, 2024 | finanznachrichten.deImmix Biopharma reports promising CAR-T therapy resultsDecember 19, 2024 | uk.investing.comJournal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 16, 2024 | globenewswire.comImmix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024December 10, 2024 | globenewswire.comWill Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?December 10, 2024 | uk.finance.yahoo.comImmix Biopharma to Host Conference Call for Investors, Analysts and Members of the MediaDecember 9, 2024 | globenewswire.comImmix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology ...November 26, 2024 | bakersfield.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRX, IMMX, APLT, and GANX Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Applied Therapeutics NASDAQ:APLT$0.49 +0.05 (+10.25%) As of 04:00 PM EasternApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Gain Therapeutics NASDAQ:GANX$1.86 -0.07 (-3.63%) As of 04:00 PM EasternGain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Immix Biopharma NASDAQ:IMMX$1.98 0.00 (0.00%) As of 04:00 PM EasternImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
